SCHEMBL3974470

SCHEMBL3974470

CC(=O)OCc1ccc(C)o1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
ALOX5 P09917 1/20 0.46
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
CHRM1 P11229 1/20 0.42
CYP2C9 P11712 1/20 0.42
CHRM3 P20309 1/20 0.42
MAPT P10636 2/20 0.41
TSHR P16473 1/20 0.40
CYP3A4 P08684 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HPGD P15428 1/20 0.39
LMNA P02545 2/20 0.38
HSD17B10 Q99714 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2541634 0.88 ALDH1A1 (0.60) ALDH1A1MEN1KMT2AMAPTTSHR
SCHEMBL16358205 0.83 ALOX5 (0.53) ALDH1A1ALOX5MEN1KMT2ACHRM2
SCHEMBL18294967 0.81 ALDH1A1 (0.50) ALDH1A1MEN1KMT2ACYP2C9MAPT
SCHEMBL257112 0.81 ALDH1A1 (0.53) ALDH1A1MEN1KMT2AMAPTTSHR
SCHEMBL5856909 0.81 ALDH1A1 (0.53) ALDH1A1MEN1KMT2ACYP2C9MAPT
SCHEMBL10261585 0.81 ALDH1A1 (0.53) ALDH1A1MEN1KMT2ATSHRCYP3A4
SCHEMBL25987625 0.80 SMN1; SMN2 (0.52) ALDH1A1MEN1KMT2AMAPTTSHR
SCHEMBL17485847 0.79 ALDH1A1 (0.51) ALDH1A1ALOX5MEN1KMT2AMAPT
SCHEMBL4140284 0.79 ALDH1A1 (0.51) ALDH1A1ALOX5MEN1KMT2ACYP2C9
SCHEMBL19940614 0.79 ALDH1A1 (0.51) ALDH1A1MEN1KMT2AMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11851608-B2 Compositions and methods for deep penetration treatments of fines migration and sand control in clay-laden formations HALLIBURTON ENERGY SERVICES, INC. (US) 2023-12-26 US claimed
US-20230183555-A1 Compositions And Methods For Deep Penetration Treatments Of Fines Migration And Sand Control In Clay-Laden Formations HALLIBURTON ENERGY SERVICES, INC. (US) 2023-06-15 US claimed
US-20090111865-A1 Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof ASTRAZENECA AB (SE) 2009-04-30 US claimed
US-7517898-B2 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof ASTRAZENECA AB (SE) 2009-04-14 US claimed
US-7501447-B2 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof ASTRAZENECA AB (SE) 2009-03-10 US claimed
US-7407968-B2 Compounds ASTRAZENECA AB (SE) 2008-08-05 US claimed
US-7244850-B2 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof ASTRAZENECA AB (SE) 2007-07-17 US claimed
US-20070105893-A1 Novel Compounds ASTRAZENECA AB R&D HEADQUARTERS GLOBAL INTELLECTUAL PROPERTY PATENTS (SE) 2007-05-10 US claimed
US-20070060583-A1 Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof ASTRAZENECA AB (SE) 2007-03-15 US claimed
JP-2006527248-A 2006-11-30 JP claimed
EP-1636194-A1 BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF AstraZeneca AB (SE) 2006-03-22 EP claimed
EP-1636214-A1 BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF Astrazeneca AB (SE) 2006-03-22 EP claimed
EP-1554254-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2005-07-20 EP claimed
WO-2004108688-A1 BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF ASTRAZENECA AB (SE) 2004-12-16 WO claimed
WO-2004108712-A1 BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF ASTRAZENECA AB (SE) 2004-12-16 WO claimed
WO-2004108689-A1 BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF ASTRAZENECA AB (SE) 2004-12-16 WO claimed
US-20040116465-A1 Novel compounds ASTRAZENECA AB (SE) 2004-06-17 US claimed
WO-2004035548-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2004-04-29 WO claimed
EP-1390350-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2004-02-25 EP claimed
WO-2002085866-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2002-10-31 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111865-A1 Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof H1-3, H1-4, CYP3A4 ALDH1A1 429/4885ALOX5 1986/4885MEN1 2990/4885
US-20070105893-A1 Novel Compounds CNR1, CNR2, OPRL1 ALDH1A1 2405/4885ALOX5 341/4885MEN1 3973/4885
US-20070060583-A1 Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof BTF3, TYMS, F3 ALDH1A1 1603/4885ALOX5 2523/4885MEN1 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.